Hiroaki Nagai
Research Subjects
Hiroaki Nagai has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hidehisa Iwata
Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
2 shared publications Masayo Saito
Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
2 shared publicationsAkiko Abiru
Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan
1 shared publicationHiromitsu Fuse
Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan
1 shared publicationHiroshi Inooka
Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
1 shared publicationHisashi Fujita
Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
1 shared publication
Latest Publications
- Open Access
- 6 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Direct conversion of urine-derived cells into functional motor neuron-like cells by defined transcription factors
Direct cell-type conversion of somatic cells into cell types of interest has garnered great attention because it circumvents rejuvenation and preserves the hallmarks of cellular aging (unlike induced pluripotent stem cells [iPSCs]) and is more suitable for modeling diseases with strong age-related and epigenetic contributions. Fibroblasts are commonly used for direct conversion; however, obtaining these cells requires highly invasive skin biopsies. Urine-derived cells (UDCs) are an alternative cell source and can be obtained via noninvasive procedures. Herein, induced motor neuron-like cells (iMNs) were generated from UDCs by transducing transcription factors involved in motor neuron (MN) differentiation. iMNs exhibited neuronal morphology, upregulation of pan-neuron and MN markers, and MN functionality, including spontaneous calcium oscillation and bungarotoxin-positive neuromuscular junction formation, when co-cultured with myotubes. Altogether, the findings of this study indicated that UDCs can be converted to functional MNs. This technology may allow us to understand disease pathogenesis and progression and discover biomarkers and drugs for MN-related diseases at the population level.
- 6 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessDirect conversion of urine-derived cells into functional motor neuron-like cells by defined transcription factors
Direct cell-type conversion of somatic cells into cell types of interest has garnered great attention because it circumvents rejuvenation and preserves the hallmarks of cellular aging (unlike induced pluripotent stem cells [iPSCs]) and is more suitable for modeling diseases with strong age-related and epigenetic contributions. Fibroblasts are commonly used for direct conversion; however, obtaining these cells requires highly invasive skin biopsies. Urine-derived cells (UDCs) are an alternative cell source and can be obtained via noninvasive procedures. Herein, induced motor neuron-like cells (iMNs) were generated from UDCs by transducing transcription factors involved in motor neuron (MN) differentiation. iMNs exhibited neuronal morphology, upregulation of pan-neuron and MN markers, and MN functionality, including spontaneous calcium oscillation and bungarotoxin-positive neuromuscular junction formation, when co-cultured with myotubes. Altogether, the findings of this study indicated that UDCs can be converted to functional MNs. This technology may allow us to understand disease pathogenesis and progression and discover biomarkers and drugs for MN-related diseases at the population level.
- Open Access
- 9 December 2020
- Published by Wiley in FEBS Open Bio
- Vol. 11 (2) , 494-506
Quantitative comparison of the mRNA content of human iPSC‐derived motor neurons and their extracellular vesicles
Extracellular vesicles (EVs) contain various cargo molecules, including RNAs and proteins. EVs, which include exosomes, are predicted to be suitable surrogates of their source cells for liquid biopsy to measure biomarkers. Several studies have performed qualitative comparisons of cargo molecule repertoires between source cells and their EVs. However, quantitative comparisons have not been reported so far. Furthermore, many studies analyzed microRNAs or proteins in EVs, but not mRNAs. In this study, we analyzed mRNAs in motor neurons and their EVs. Normal human‐induced pluripotent stem cells were differentiated into motor neurons, and comprehensive analysis of mRNAs in the cells and their EVs was performed by RNA sequencing. Differential analysis between cellular and EV mRNAs was performed by edgeR after normalization of read count. The results suggest that signatures in the abundance of EV mRNAs were different from those of cellular mRNAs. Comparison of intracellular vesicle and EV mRNA abundance showed negatively and positively biased genes in the EVs. Gene Ontology analysis revealed that the genes showing negatively biased abundance in the EVs were enriched in many functions regarding neuronal development. In contrast, the positively biased genes were enriched in functions regarding cellular metabolism and protein synthesis. These results suggest that mRNAs in motor neurons are loaded into EVs to regulate certain mechanisms, which are yet to be elucidated.
- 9 December 2020
- Published by Wiley in FEBS Open Bio
- Vol. 11 (2) , 494-506
Open AccessQuantitative comparison of the mRNA content of human iPSC‐derived motor neurons and their extracellular vesicles
Extracellular vesicles (EVs) contain various cargo molecules, including RNAs and proteins. EVs, which include exosomes, are predicted to be suitable surrogates of their source cells for liquid biopsy to measure biomarkers. Several studies have performed qualitative comparisons of cargo molecule repertoires between source cells and their EVs. However, quantitative comparisons have not been reported so far. Furthermore, many studies analyzed microRNAs or proteins in EVs, but not mRNAs. In this study, we analyzed mRNAs in motor neurons and their EVs. Normal human‐induced pluripotent stem cells were differentiated into motor neurons, and comprehensive analysis of mRNAs in the cells and their EVs was performed by RNA sequencing. Differential analysis between cellular and EV mRNAs was performed by edgeR after normalization of read count. The results suggest that signatures in the abundance of EV mRNAs were different from those of cellular mRNAs. Comparison of intracellular vesicle and EV mRNA abundance showed negatively and positively biased genes in the EVs. Gene Ontology analysis revealed that the genes showing negatively biased abundance in the EVs were enriched in many functions regarding neuronal development. In contrast, the positively biased genes were enriched in functions regarding cellular metabolism and protein synthesis. These results suggest that mRNAs in motor neurons are loaded into EVs to regulate certain mechanisms, which are yet to be elucidated.
- 18 December 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (2) , 359-373
Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice
Background and Purpose: Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU‐mediated anti‐obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor‐selective agonists.Experimental Approach: Efficacy and safety were assessed in mice with diet‐induced obesity (DIO) and those with leptin‐deficient diabetes (ob/ob) through repeated peripheral administration of selective agonists to NMU1 (NMU‐6102) and NMU2 (NMU‐2084), along with non‐selective NMU1/2 agonists (NMU‐0002 and NMU‐6014). We also performed immunohistochemistry for c‐Fos protein expression in the brain to probe their mechanisms of action.Key Results: Although both non‐selective NMU1/2 agonists and the NMU2‐selective agonist had high efficacy compared with the NMU1‐selective agonist, only the NMU2‐selective agonist led to relatively low adverse effects, such as diarrhoea, in DIO mice. However, the non‐selective NMU1/2 agonist and the NMU1‐selective agonist, but not the NMU2‐selective agonist, were effective in diabetic ob/ob mice. Mechanistically, NMU2‐selective agonists preferentially activate pro‐opiomelanocortin neurons in the hypothalamic arcuate nucleus but not in the paraventricular nucleus.Conclusions and Implications: These results suggest that an NMU2 receptor‐selective agonist may be a well‐balanced drug for the treatment of obesity and that an NMU1 receptor‐selective agonist may also be beneficial for treating obesity and diabetes once its side effects are minimized.
- 18 December 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (2) , 359-373
Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice
Background and Purpose: Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU‐mediated anti‐obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor‐selective agonists.Experimental Approach: Efficacy and safety were assessed in mice with diet‐induced obesity (DIO) and those with leptin‐deficient diabetes (ob/ob) through repeated peripheral administration of selective agonists to NMU1 (NMU‐6102) and NMU2 (NMU‐2084), along with non‐selective NMU1/2 agonists (NMU‐0002 and NMU‐6014). We also performed immunohistochemistry for c‐Fos protein expression in the brain to probe their mechanisms of action.Key Results: Although both non‐selective NMU1/2 agonists and the NMU2‐selective agonist had high efficacy compared with the NMU1‐selective agonist, only the NMU2‐selective agonist led to relatively low adverse effects, such as diarrhoea, in DIO mice. However, the non‐selective NMU1/2 agonist and the NMU1‐selective agonist, but not the NMU2‐selective agonist, were effective in diabetic ob/ob mice. Mechanistically, NMU2‐selective agonists preferentially activate pro‐opiomelanocortin neurons in the hypothalamic arcuate nucleus but not in the paraventricular nucleus.Conclusions and Implications: These results suggest that an NMU2 receptor‐selective agonist may be a well‐balanced drug for the treatment of obesity and that an NMU1 receptor‐selective agonist may also be beneficial for treating obesity and diabetes once its side effects are minimized.
- Open Access
- 1 October 2017
- Published by Elsevier in EBioMedicine
- Vol. 24, 147-158
Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia
- 1 October 2017
- Published by Elsevier in EBioMedicine
- Vol. 24, 147-158
Open AccessAntihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia